Results 1 to 10 of about 6,313 (203)

IDeglira vs insulin degludec for type 2 diabetes: a systematic review and meta-analysis [PDF]

Frontiers in Endocrinology
ObjectivesThis systematic review and meta-analysis was to evaluate and compare the efficacy and safety profiles of IDegLira versus insulin degludec in the management of type 2 diabetes (T2D).MethodsA comprehensive search was systematically conducted ...
Yang Liu, Xuejing Li, Jie Yang, Suhui Qie, Xiaoli Wang, Xianying Wang, Yingying Zheng   +6 more
doaj   +2 more sources

Degludec insulin: A novel basal insulin

Indian Journal of Endocrinology and Metabolism, 2011
This paper reviews a novel insulin analogue, degludec, which has the potential to emerge as an ideal basal insulin. It reviews the limitations of existing basal insulin and analogues, and highlights the need for a newer molecule.
Sanjay Kalra, Ambika Gopalakrishnan Unnikrishnan, Manash Baruah, Bharti Kalra   +3 more
doaj   +3 more sources

Insulin degludec

Journal of Mahatma Gandhi Institute of Medical Sciences, 2013
Insulin analogues have revolutionized the treatment of diabetes mellitus, and the advent of newer insulin analogues have provided better glycemic control with lesser incidence of hypoglycemia.
Vishakha V Jain, Omprakash Gupta
doaj   +2 more sources

Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once‐Weekly Basal Insulin Fc Versus Insulin Degludec: A Systematic Review and Meta‐Analysis [PDF]

Endocrinology, Diabetes & Metabolism
Introduction Once‐weekly basal insulin Fc (BIF) offers a promising alternative to daily basal insulin by reducing injection burden while maintaining glycaemic control.
Saaed Abunada, Sheela Bai, Usha Kumari, F. N. U. Nancy, Areeba Khan, Nikeeta Bai, F. N. U. Shevani, Anusha Bai, Shah Dev, Noshad Zain ul Abiddin, F. N. U. Umer, Abdul Manan, Sadia Habib Bhutto, Salih Abdella Yusuf   +13 more
doaj   +2 more sources

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience

Indian Journal of Endocrinology and Metabolism, 2016
This study aimed to document the utility and safety of insulin degludec (IDeg) and insulin degludec aspart (IDegAsp) in persons with type 2 diabetes, observing the Ramadan fast.
Sanjay Kalra
doaj   +3 more sources

Healthcare utilization and costs in adults with type 2 diabetes treated with first or second-generation basal insulins in England [PDF]

BMJ Open Diabetes Research & Care
Introduction The prevalence of people with type 2 diabetes (T2D) on basal insulin (BI) is rising to improve glucose control and minimize complications.
Iskandar Idris, Amar Puttanna, Karen Palmer, Fatemeh Saberi Hosnijeh, Neil Holden, Aymeric Mahieu, Onyinye Diribe, Charlie Nicholls, Xiaocong Li Marston, Nick Denholm   +9 more
doaj   +2 more sources

Transition from Continuous Subcutaneous Insulin Infusion to IDeg-Based Regimens in Hospitalized T2DM Patients: A Single-Center Retrospective Analysis [PDF]

Diabetes, Metabolic Syndrome and Obesity
Ruiqing Dong,1,* Lifan Gu,2,* Heping Li,1 Yuanna Hu,3 Hui Liu,4 Xuna Kou,1 Yukun Zhao,1 Meng Zhao,1 Bingyin Shi,1 Hui Guo,1 Wei Qiang1 1Department of Endocrinology and Metabolism, The First Affiliated Hospital of Xi’an Jiaotong University,
Dong R, Gu L, Li H, Hu Y, Liu H, Kou X, Zhao Y, Zhao M, Shi B, Guo H, Qiang W   +10 more
doaj   +1 more source

A cost-utility analysis of long-acting insulin analogues (detemir, glargine and degludec) for the treatment of adult type 1 diabetes in South Africa [PDF]

Cost Effectiveness and Resource Allocation
Background Type 1 Diabetes Mellitus (T1DM) is a life-threatening condition that is managed with administered insulin. Intermediate- to long-acting insulin represents the basal insulin constituent of the total insulin used in treating T1DM.
Mark T. Verryn, Susan Cleary
doaj   +2 more sources

Efficacy and safety of the fixed‐ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials

Journal of Diabetes Investigation, 2021
Aims/Introduction To assess efficacy and safety of insulin degludec/liraglutide (IDegLira) in Japanese participants with type 2 diabetes across different baseline characteristics. Materials and Methods Data from two randomized controlled trials were used:
Mitsuhisa Komatsu, Hirotaka Watada, Shizuka Kaneko, Bue F Ross Agner, Tomoyuki Nishida, Kohei Kaku   +5 more
doaj   +1 more source

One-year safety and effectiveness of insulin degludec in patients with diabetes mellitus in routine clinical practice in India—TRUST (Tresiba real-world use study)

Metabolism Open, 2022
Objective: This post-authorization safety study (PASS) was conducted to evaluate the long-term safety and effectiveness of insulin degludec in patients with diabetes mellitus (DM) requiring insulin therapy in routine clinical practice in India.
Jothydev Kesavadev, L.Sreenivasa Murthy, Tirthankar Chaudhury, Sadasiva Rao Yalamanchi, J. Giri, Sunil Gupta, Sanjeev Phatak, K.D. Modi, Sanjay Chatterjee, Aparna Manjunath, Manjunatha Revanna, Arpandev Bhattacharya   +11 more
doaj   +1 more source